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Aim: The aim of the present study was to evaluate the efficacy and safety of narrowband UVB 
(NB-UVB) compared with tacrolimus ointment 0.1% in patients with bilateral vitiligo. Methods: In 
this comparative study, four groups of patients were randomized. Each group was composed by 12 
patients with bilateral vitiligo; in each group, every patient was irradiated with NB-UVB (length: 
311 nm) twice a week for 9 months and applied tacrolimus ointment 0.1% twice a day on the other 
area in the same period. Before starting therapy and after 3, 6 and 9 months of therapy, a clinical 
and photographic evaluation of percentage of repigmentation was performed and Dermatology Life 
Quality Index Questionnaire was fulfilled. Results: A repigmentation at least partial occurred in 
71% of patients after 36 weeks of treatment with tacrolimus ointment 0.1%; in the whole sample, 14 
patients (29%) showed no repigmentation at all, with 2 of them discontinuing the therapy because 
of side effects (erythema and folliculitis-like manifestations). A homogeneous repigmentation at 
least partial occurred in 69% of patients after 36 weeks of treatment with NB-UVB; in the whole 
sample 15 patients (31%) showed no repigmentation at all, with 1 of them discontinuing the therapy 
because of side effects. Conclusion: The present study confirmed that the efficacy of NB-UVB 
phototherapy in vitiligo is comparable to tacrolimus ointment 0.1% therapy. On the basis of our 
study, we may suggest tacrolimus ointment 0.1% as an alternative to NB-UVB therapy for treating 
vitiligo.  
 
